Phase 3 studies involving asundexian, milvexian, and abelacimab
| Study drug . | Trial . | Comparator . | Estimated enrollment . | Patients and primary outcome . |
|---|---|---|---|---|
| Asundexian | OCEANIC-STROKE | Placebo | 9 300 | Patients: acute noncardioembolic ischemic stroke or high-risk transient ischemic attack Efficacy: time to first occurrence of ischemic stroke Safety: time to first occurrence of ISTH major bleeding |
| OCEANIC-AF | Apixaban | 18 000 | Patients: atrial fibrillation at risk of stroke Efficacy: time to first occurrence of stroke or systemic embolism Safety: time to first occurrence of ISTH major bleeding | |
| Milvexian | LIBREXIA-ACS | Placebo | 16 000 | Patients: acute coronary syndrome, with percutaneous intervention or conservative treatment, on antiplatelet agents Efficacy: time to occurrence of ischemic stroke |
| LIBREXIA-STROKE | Placebo | 15 000 | Patients: acute stroke or high-risk transient ischemic attack on antiplatelet therapy Efficacy: time to occurrence of major adverse cardiovascular event (death, MI, or stroke) | |
| LIBREXIA-AF | Apixaban | 15 500 | Patients: atrial fibrillation Efficacy: time to first occurrence of stroke or non–central nervous system embolization | |
| Abelacimab | LILAC-TIMI 76 | Placebo | 1 900 | Patients: patients who are at high risk with atrial fibrillation deemed unsuitable for oral anticoagulation Efficacy: time to first ischemic stroke or systemic symbolism Safety: time to first occurrence of BARC type 3c/5 bleeding |
| ASTER | Apixaban | 1 655 | Patients: patients with cancer with venous thromboembolism Efficacy: time to VTE recurrence (new deep vein thrombosis, new pulmonary embolism, or fatal pulmonary embolism) | |
| MAGNOLIA | Dalteparin | 1 020 | Patients: gastrointestinal and genitourinary cancers with venous thromboembolism Efficacy: time to VTE recurrence (new deep vein thrombosis, new pulmonary embolism, or fatal pulmonary embolism) |
| Study drug . | Trial . | Comparator . | Estimated enrollment . | Patients and primary outcome . |
|---|---|---|---|---|
| Asundexian | OCEANIC-STROKE | Placebo | 9 300 | Patients: acute noncardioembolic ischemic stroke or high-risk transient ischemic attack Efficacy: time to first occurrence of ischemic stroke Safety: time to first occurrence of ISTH major bleeding |
| OCEANIC-AF | Apixaban | 18 000 | Patients: atrial fibrillation at risk of stroke Efficacy: time to first occurrence of stroke or systemic embolism Safety: time to first occurrence of ISTH major bleeding | |
| Milvexian | LIBREXIA-ACS | Placebo | 16 000 | Patients: acute coronary syndrome, with percutaneous intervention or conservative treatment, on antiplatelet agents Efficacy: time to occurrence of ischemic stroke |
| LIBREXIA-STROKE | Placebo | 15 000 | Patients: acute stroke or high-risk transient ischemic attack on antiplatelet therapy Efficacy: time to occurrence of major adverse cardiovascular event (death, MI, or stroke) | |
| LIBREXIA-AF | Apixaban | 15 500 | Patients: atrial fibrillation Efficacy: time to first occurrence of stroke or non–central nervous system embolization | |
| Abelacimab | LILAC-TIMI 76 | Placebo | 1 900 | Patients: patients who are at high risk with atrial fibrillation deemed unsuitable for oral anticoagulation Efficacy: time to first ischemic stroke or systemic symbolism Safety: time to first occurrence of BARC type 3c/5 bleeding |
| ASTER | Apixaban | 1 655 | Patients: patients with cancer with venous thromboembolism Efficacy: time to VTE recurrence (new deep vein thrombosis, new pulmonary embolism, or fatal pulmonary embolism) | |
| MAGNOLIA | Dalteparin | 1 020 | Patients: gastrointestinal and genitourinary cancers with venous thromboembolism Efficacy: time to VTE recurrence (new deep vein thrombosis, new pulmonary embolism, or fatal pulmonary embolism) |